AbbVie Inc (ABBV)vsApellis Pharmaceuticals Inc (APLS)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
APLS
Apellis Pharmaceuticals Inc
$41.03
0.00%
HEALTHCARE · Cap: $5.25B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 5725% more annual revenue ($64.39B vs $1.11B). APLS leads profitability with a 12.1% profit margin vs 9.8%. APLS trades at a lower P/E of 38.3x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
APLS
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Margin of Safety
+88.5%
Fair Value
$194.37
Current Price
$41.03
$153.34 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Every $100 of equity generates 33 in profit
Revenue surging 60.9% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Premium valuation, high expectations priced in
Trading at 12.7x book value
0.0% earnings growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : APLS
The strongest argument for APLS centers on Return on Equity, Revenue Growth. Revenue growth of 60.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : APLS
The primary concerns for APLS are P/E Ratio, Price/Book, EPS Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while APLS is a growth play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.28 — expect wider price swings.
APLS is growing revenue faster at 60.9% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 50/100) and 10.2% revenue growth. APLS offers better value entry with a 88.5% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Apellis Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?